What's Going On With ImmunityBio Stock?
Portfolio Pulse from Erica Kollmann
ImmunityBio, Inc. (NASDAQ:IBRX) shares surged after announcing positive overall survival results in its QUILT 3.055 study for NSCLC patients. The trial showed median overall survival nearly double that of standard chemotherapy. Additionally, the FDA approved ImmunityBio's Anktiva plus BCG for NMIBC. Trading volume spiked, with over 26.6 million shares traded compared to the 100-day average of 4.774 million.
April 26, 2024 | 7:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio's stock price surged following the announcement of positive results from its QUILT 3.055 study and FDA approval of Anktiva for NMIBC.
The positive outcome of the QUILT 3.055 study and the FDA approval of Anktiva for NMIBC are significant milestones for ImmunityBio. These developments are likely to boost investor confidence, reflecting positively on the stock price in the short term. The substantial increase in trading volume indicates heightened investor interest and potential for continued upward momentum.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100